(Q37899800)

25 August 2017

2 references

19 September 2019

22 August 2022

Immunogenicity of therapeutic proteins: the use of animal models (English)

1 reference

biomedical investigative technique

25 August 2017

1 reference

19 September 2019

2

Wim Jiskoot

1 reference

25 August 2017

Vera Brinks

1

1 reference

25 August 2017

Huub Schellekens

series ordinal

3

1 reference

25 August 2017

9 July 2011

1 reference

25 August 2017

1 October 2011

2 references

19 September 2019

22 August 2022

Pharmaceutical Research

3 references

25 August 2017

19 September 2019

22 August 2022

28

1 reference

25 August 2017

10

1 reference

25 August 2017

2379-2385

1 reference

Creative Commons Attribution-NonCommercial 4.0 International

25 August 2017

1 reference

Mechanisms of adverse drug reactions to biologics

22 August 2022

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170476

Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170476

Dealing with immunogenicity of biologicals: assessment and clinical relevance

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170476

Principles, approaches, and challenges for predicting protein aggregation rates and shelf life

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170476

Immunogenicity of protein therapeutics

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170476

The Rebif new formulation story: it's not trials and error

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170476

Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170476

Factors influencing the immunogenicity of therapeutic proteins

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170476

Immunologic mechanisms of EPO-associated pure red cell aplasia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170476

Immunogenicity of interferon beta: differences among products

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170476

Immunogenicity of therapeutic proteins: clinical implications and future prospects

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170476

Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170476

In vivo characterization of sustained-release formulations of human growth hormone.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170476

Tolerance induced by physiological levels of secreted proteins in transgenic mice expressing human insulin

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170476

Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170476

Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170476

Transgenic mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170476

Immunogenic properties of structurally modified human tissue plasminogen activators in chimpanzees and mice.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170476

Requirements for the natural killer cell-mediated induction of IgG1 and IgG2a expression in B lymphocytes

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170476

Immunogenicity comparison of interferon beta-1a preparations using the BALB/c mouse model: assessment of a new formulation for use in multiple sclerosis.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170476

Development of a transgenic mouse model immune tolerant for human interferon Beta.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170476

The use of an animal immunogenicity model in the development of Protropin somatrem (methionyl human growth hormone).

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3170476

Antibody Response to Aggregated Human Interferon Alpha2b in Wild-type and Transgenic Immune Tolerant Mice Depends on Type and Level of Aggregation

1 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11095-011-0523-5

Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo

21 January 2018

1 reference

12 December 2020

The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model

1 reference

12 December 2020

Comparison of the immunogenicity of recombinant and pituitary human growth hormone in rhesus monkeys

1 reference

12 December 2020

Immunogenicity of biosynthetic human LysPro insulin compared to native-sequence human and purified porcine insulins in rhesus monkeys immunized over a 6-week period

1 reference

12 December 2020

Immunogenicity of tissue plasminogen activators in rhesus monkeys: antibody formation and effects on blood level and enzymatic activity

1 reference

12 December 2020

Immunogenicity of recombinant human interleukin-3

1 reference

12 December 2020

Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice

1 reference

12 December 2020

Immunogenicity, efficacy and adverse events of adalimumab in RA patients

1 reference

12 December 2020

The immunogenicity of therapeutic proteins and the Fabry antibody standardization initiative

1 reference

12 December 2020

Immunogenicity of aggregates of recombinant human growth hormone in mouse models

1 reference

12 December 2020

Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation

1 reference

12 December 2020

Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta

1 reference

12 December 2020

Immunological mechanism underlying the immune response to recombinant human protein therapeutics

1 reference

12 December 2020

The immunogenicity of therapeutic proteins

1 reference

12 December 2020

n-Dodecyl-β-D-maltoside inhibits aggregation of human interferon-β-1b and reduces its immunogenicity

1 reference

12 December 2020

10.1007/S11095-011-0523-5

Identifiers

DOI

1 reference

25 August 2017

1 reference

25 August 2017

PubMed publication ID

21744171

1 reference